News >

Frontline Pembrolizumab Improves Survival at Lower PD-L1 Threshold

Jason M. Broderick @jasoncology
Published: Monday, Apr 09, 2018

Tony Mok, MD
Tony Mok, MD
Single-agent treatment with the PD-1 inhibitor pembrolizumab (Keytruda) improved overall survival (OS) versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a PD-L1 expression level ≥1%.

The approval was based on part 2 of cohort G in the KEYNOTE-021 trial, which showed that the frontline combination of pembrolizumab, pemetrexed, and carboplatin reduced the risk of progression or death compared with chemotherapy alone for patients with advanced nonsquamous NSCLC. Updated results for the study were presented at the 2017 ESMO Congress.2

At median follow-up of 18.7 months, the overall response rate was 56.7% for the pemetrexed arm compared with 31.7% with pemetrexed and carboplatin alone (95% CI, 7.2-40.9; P = .0029). The risk of progression or death was reduced by 46% with pembrolizumab (HR, 0.54; 95% CI, 0.33-0.88; P = .0067). There was also a trend toward an OS improvement with pembrolizumab (HR, 0.59; 95% CI, 0.34-1.05; P = .03). 

Beyond the frontline, pembrolizumab is also approved in NSCLC as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved targeted therapies for these aberrations, according to the FDA label.

References

  1. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD-L1 TPS ≥50%. Presented at: the IASLC 18th World Conference on Lung Cancer; October 15-18; Yokohama, Japan. Abstract OA 17.06 (ID 9582).
  2. Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC. https://bit.ly/2ExmUXK . Published online September 8, 2017. Accessed April 9, 2018.

 



... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Articles
Blogs
Conference Coverage
OncLive TV
Peer Exchange
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.
 
x